Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric rivaroxaban versus standard anticoagulation for acute venous thromboembolism
NL-OMON47378Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rivaroxaban in venous thromboembolism (VTE) (3 arms), sponsored by Bayer. Primary endpoint: Primary efficacy endpoint. Started Dec 2014; status: active, not recruiting.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NL-OMON47378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47378.